Xenetic Biosciences is trading 6.3% up now at $3.02 after reporting a $930,000 quarterly loss.
- Second-quarter 2026 results, released August 7, 2026, included a loss of $0.41 per share and $661,000 in revenue.
- First-half royalty revenue reached approximately $1.5 million; DNase I preclinical data were positive, and a partner’s exploratory lymphoma study was approved.
- Biotech-sector strength, including M&A optimism, provided additional support.